CA2447564A1 - Acides nucleiques et proteines correspondantes dits 101p3a11 ou phor-1 servant au traitement et a la detection de cancers - Google Patents
Acides nucleiques et proteines correspondantes dits 101p3a11 ou phor-1 servant au traitement et a la detection de cancers Download PDFInfo
- Publication number
- CA2447564A1 CA2447564A1 CA002447564A CA2447564A CA2447564A1 CA 2447564 A1 CA2447564 A1 CA 2447564A1 CA 002447564 A CA002447564 A CA 002447564A CA 2447564 A CA2447564 A CA 2447564A CA 2447564 A1 CA2447564 A1 CA 2447564A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- 1o1p3a11
- antibody
- cells
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention porte sur un nouveau gène (dit 101P3A11 ou PHOR-1), sur la protéine correspondante et sur leurs variantes, le 101P3A11 présentant une expression spécifique dans les tissus adultes normaux, et une expression aberrante dans les cancers répertoriés dans la table (I). En conséquence le 101P3A11 constitue une cible pouvant servir pour les diagnostics, les pronostiques, la prophylaxie et la thérapie du cancer. Le gène 101P3A11 ou ses fragments ou la protéine correspondante, ou leurs variantes peuvent servir à provoquer une réponse immunitaire humorale ou cellulaire. Les anticorps ou cellules T réagissant avec le 101P3A11 peuvent servir à des immunisation actives ou passives.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29111801P | 2001-05-15 | 2001-05-15 | |
US60/291,118 | 2001-05-15 | ||
US10/001,469 | 2001-10-31 | ||
US10/001,469 US7208280B2 (en) | 1999-10-05 | 2001-10-31 | Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer |
US10/017,066 | 2001-12-14 | ||
US10/017,066 US6838258B2 (en) | 1999-10-05 | 2001-12-14 | G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
PCT/US2002/015520 WO2002092842A2 (fr) | 2001-05-15 | 2002-05-15 | Acides nucleiques et proteines correspondantes dits 101p3a11 ou phor-1 servant au traitement et a la detection de cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2447564A1 true CA2447564A1 (fr) | 2002-11-21 |
Family
ID=38616826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002447564A Abandoned CA2447564A1 (fr) | 2001-05-15 | 2002-05-15 | Acides nucleiques et proteines correspondantes dits 101p3a11 ou phor-1 servant au traitement et a la detection de cancers |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1539805A4 (fr) |
JP (1) | JP2005512509A (fr) |
AU (2) | AU2002309873B2 (fr) |
CA (1) | CA2447564A1 (fr) |
IL (1) | IL158860A0 (fr) |
WO (1) | WO2002092842A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7361338B2 (en) | 1999-10-05 | 2008-04-22 | Agensys, Inc. | Methods to inhibit growth of prostate cancer cells |
US7208280B2 (en) | 1999-10-05 | 2007-04-24 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer |
US6790631B1 (en) | 1999-10-05 | 2004-09-14 | Agensys, Inc. | G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
AU2004217526B2 (en) | 2003-02-28 | 2010-02-04 | St. Jude Children's Research Hospital Inc. | T cell regulation |
JP5122592B2 (ja) * | 2010-01-04 | 2013-01-16 | アジェンシス,インコーポレイテッド | 癌の処置および検出において有用な24p4c12と称される、核酸および対応タンパク質 |
US10722563B2 (en) * | 2012-09-20 | 2020-07-28 | Shenzhen Innovation Immunotechnology Co., Ltd. | Prostate-specific tumor antigens and uses thereof |
CN111549140B (zh) * | 2020-06-08 | 2023-08-08 | 重庆医科大学附属第一医院 | 一种检测肺癌相关基因C2orf40、FIBIN和GRP甲基化的试剂盒及其应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2367640T3 (es) * | 1996-03-11 | 2011-11-07 | Epimmune Inc. | Péptidos con afinidad de unión aumentada para al menos tres moléculas de tipo hla-a3. |
US6800746B2 (en) * | 1997-02-25 | 2004-10-05 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
WO2000020590A2 (fr) * | 1998-10-06 | 2000-04-13 | Incyte Pharmaceuticals, Inc. | Proteines de recepteurs couples a des proteines g |
WO2000044775A2 (fr) * | 1999-01-27 | 2000-08-03 | Epimmune Inc. | Identification d'epitopes de cellules t restreintes au hla et fortement reactives |
ATE417104T1 (de) * | 1999-10-05 | 2008-12-15 | Agensys Inc | G protein-gekoppelter in prostatakrebs hochexprimierter rezeptor und seine verwendungen |
US7361338B2 (en) * | 1999-10-05 | 2008-04-22 | Agensys, Inc. | Methods to inhibit growth of prostate cancer cells |
AU2903701A (en) * | 1999-10-08 | 2001-04-23 | Digiscents | Olfactory receptor sequences |
EP1299528A4 (fr) * | 2000-03-13 | 2005-10-05 | Senomyx Inc | Nouveaux recepteurs olfactifs humains et genes codant ces recepteurs |
AU2001249549A1 (en) * | 2000-03-27 | 2001-10-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
WO2001074904A2 (fr) * | 2000-03-31 | 2001-10-11 | Curagen Corporation | Nouvelles proteines et acides nucleiques codant pour celles-ci |
US20030022237A1 (en) * | 2000-09-27 | 2003-01-30 | Feder John N. | Novel human G-protein coupled receptor, HGPRBMY4, expressed highly in prostate, colon, and lung |
WO2002061087A2 (fr) * | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques |
US20030108963A1 (en) * | 2001-07-25 | 2003-06-12 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer |
-
2002
- 2002-05-15 AU AU2002309873A patent/AU2002309873B2/en not_active Ceased
- 2002-05-15 JP JP2002589708A patent/JP2005512509A/ja active Pending
- 2002-05-15 IL IL15886002A patent/IL158860A0/xx unknown
- 2002-05-15 WO PCT/US2002/015520 patent/WO2002092842A2/fr active Search and Examination
- 2002-05-15 EP EP02736898A patent/EP1539805A4/fr not_active Withdrawn
- 2002-05-15 CA CA002447564A patent/CA2447564A1/fr not_active Abandoned
-
2008
- 2008-01-18 AU AU2008200363A patent/AU2008200363B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2008200363B2 (en) | 2010-08-12 |
EP1539805A2 (fr) | 2005-06-15 |
WO2002092842A3 (fr) | 2005-04-21 |
AU2008200363A8 (en) | 2008-03-13 |
AU2008200363A1 (en) | 2008-02-21 |
IL158860A0 (en) | 2004-05-12 |
EP1539805A4 (fr) | 2005-11-16 |
AU2002309873B2 (en) | 2007-10-18 |
JP2005512509A (ja) | 2005-05-12 |
WO2002092842A2 (fr) | 2002-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8236510B2 (en) | Protein showing enhanced expression in cancer cells | |
US7928196B2 (en) | Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer | |
US7982004B2 (en) | Nucleic acid and corresponding protein entitled 161P5C5 useful in treatment and detection of cancer | |
US8003100B2 (en) | Antibodies that bind to 238P1B2 | |
AU2008200363B2 (en) | Nucleic acids and corresponding proteins entitled 101P3A11 or PHOR-1 useful in treatment and detection of cancer | |
US8039603B2 (en) | Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer | |
US7459539B2 (en) | Antibody that binds zinc transporter protein 108P5H8 | |
US8173381B2 (en) | Nucleic acid and corresponding protein entitled 85P1B3 useful in treatment and detection of cancer | |
WO2002014361A2 (fr) | Acides nucleiques et proteines correspondantes appeles 83p2h3 et catrf2e11 utiles dans le traitement et la detection du cancer | |
US20100086985A1 (en) | Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer | |
AU2002309873A1 (en) | Nucleic acids and corresponding proteins entitled 101P3A11 or PHOR-1 useful in treatment and detection of cancer | |
US8647826B2 (en) | Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer | |
US20030091562A1 (en) | Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer | |
WO2002014501A2 (fr) | Acides nucleiques et proteines correspondantes appelees phor1-a11 et phor1-f5d6 utiles dans le traitement et la detection du cancer | |
US20030134784A1 (en) | Nucleic acids and corresponding proteins entitled 83P2H3 and CaTrF2E11 useful in treatment and detection of cancer | |
US20120076789A1 (en) | Nucleic acid and corresponding protein entitled 121p1f1 useful in treatment and detection of cancer | |
IL158860A (en) | 101p3a11 peptides for use in vaccine preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |